{"id":"NCT01604343","sponsor":"Janssen Research & Development, LLC","briefTitle":"A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)","officialTitle":"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis Despite DMARD Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-08-15","primaryCompletion":"2015-09-02","completion":"2016-12-06","firstPosted":"2012-05-23","resultsPosted":"2018-01-11","lastUpdate":"2018-01-11"},"enrollment":1670,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Arthritis, Rheumatoid"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Sirukumab","otherNames":[]},{"type":"DRUG","name":"Sirukumab","otherNames":[]},{"type":"DRUG","name":"Sirukumab","otherNames":[]}],"arms":[{"label":"Placebo then Sirukumab 50 mg or Sirukumab 100 mg","type":"EXPERIMENTAL"},{"label":"Sirukumab 100 mg","type":"EXPERIMENTAL"},{"label":"Sirukumab 50 mg + Placebo","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the efficacy of sirukumab as measured by the reduction of the signs and symptoms of rheumatoid arthritis (RA) and inhibition of radiographic progression in patients with active RA who are unresponsive to treatment with disease-modifying antirheumatic drugs (DMARD).","primaryOutcome":{"measure":"Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 16","timeFrame":"Week 16","effectByArm":[{"arm":"Placebo","deltaMin":26.4,"sd":null},{"arm":"Sirukumab 50 mg","deltaMin":54.8,"sd":null},{"arm":"Sirukumab 100 mg","deltaMin":53.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.001"},{"comp":"OG000 vs OG002","p":"< 0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":12},"locations":{"siteCount":156,"countries":["United States","Bulgaria","Canada","Chile","Colombia","Croatia","Japan","Lithuania","Malaysia","Mexico","Poland","Romania","Russia","Serbia","South Africa","South Korea","Taiwan","Ukraine"]},"refs":{"pmids":["28855173"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":40,"n":556},"commonTop":["Alanine Aminotransferase Increased","Upper Respiratory Tract Infection","Nasopharyngitis","Aspartate Aminotransferase Increased","Injection Site Erythema"]}}